<?xml version="1.0" encoding="UTF-8"?>
<p>Pretreatment and very early treatment with anti-RSV antibodies, modestly decreases clinical findings and lung histopathology in a cotton rat model of RSV. Palivizumab an anti-RSV antibody that binds both pre- and post-fusion forms of the RSV F protein is highly effective as prophylaxis against RSV in human infants [
 <xref rid="pone.0230245.ref013" ref-type="bibr">13</xref>]but is ineffective as antiviral treatment once infection has occurred.[
 <xref rid="pone.0230245.ref014" ref-type="bibr">14</xref>] Experiments in a cotton rat model of RSV bronchiolitis demonstrated that a combination of anti-RSV antibodies and immunomodulation with NSAIDs or steroids did improve clinical outcomes following infection in a way that monotherapy did not. [
 <xref rid="pone.0230245.ref009" ref-type="bibr">9</xref>, 
 <xref rid="pone.0230245.ref015" ref-type="bibr">15</xref>]
</p>
